Modulators of androgen synthesis

Abstract

The present specification discloses compositions comprising at least one therapeutic compound capable of modulating androgen production and methods and uses for treating a disorder associated with androgen production using such compositions and/or compounds.

The invention claimed is: 
     
       1. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid. 
 
     
     
       2. The method according to  claim 1 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day. 
     
     
       3. The method according to  claim 1 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 1 mg/kg/day. 
     
     
       4. The method according to  claim 1 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
       5. The method according to  claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
       6. The method according to  claim 1 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition. 
     
     
       7. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual from 0.01 mg/kg/day to 0.5 mg/kg/day of a risperidone and from 0.01 mg/kg/day to 0.5 mg/kg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid. 
 
     
     
       8. The method according to  claim 7 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
       9. The method according to  claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
       10. The method according to  claim 7 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition. 
     
     
       11. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual a therapeutically effective amount of risperidone and from 0.1 mg/day to 20 mg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid. 
 
     
     
       12. The method according to  claim 11 , the therapeutically effective amount of risperidone is from 0.1 mg/day to 20 mg/day. 
     
     
       13. The method according to  claim 11 , wherein the therapeutically effective amount of risperidone is from 0.01 mg/kg/day to 0.5 mg/kg/day. 
     
     
       14. The method according to  claim 11 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
       15. The method according to  claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
       16. The method according to  claim 11 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition. 
     
     
       17. A method of treating an individual with a prostate cancer, the method comprising the step of administering to the individual from 0.1 mg/day to 20 mg/day of a risperidone and from 1 mg/day to 20 mg/day of a 9Z,11E conjugated Linoleic Acid, wherein administration reduces a symptom associated with the prostate cancer, thereby treating the individual,
 wherein there is a synergistic effect between the risperidone and the 9Z,11E conjugated Linoleic Acid. 
 
     
     
       18. The method according to  claim 17 , wherein the reduced symptom includes a reduction in the frequency of a symptom of a prostate cancer, a reduction in the number of symptoms of a prostate cancer, or any combination thereof. 
     
     
       19. The method according to  claim 17 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered sequentially or simultaneously. 
     
     
       20. The method according to  claim 17 , wherein the risperidone and the 9Z,11E conjugated Linoleic Acid are administered to the individual as a single composition.